Heart failure with reduced ejection fraction
CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.
Twenty questions about the protocol, each tied to the research, and what every answer does to recruitment. The answers start as this study's template; change any of them to see what moves.
All answers match the protocol.
Population and eligibility
Design
Patient burden
Operations
Environment
Build a site
A site's rate is built one factor at a time. The questionnaire sets each row, or pick an option to try a different kind of site in every country.
Poland recruits fastest per site, at 0.237 a month
Patients randomised per site per month after each factor, by countryDots: filled is evidence-anchored, half-filled takes its direction from evidence, hollow is an assumption, hatched combines several; United States highlighted
Source: epiClinical evidence library; each factor's basis and source are in the rows beside the chart.
Shaded: Industry Phase III median, 0.4. Median 0.4 patients per site per month (interquartile range 0.2 to 0.6) in completed industry Phase III trials, 2016 to 2019 (PLOS ONE 2022; D01).
Shaded: UK public trials median, 0.92 to 0.95. Median 0.92 to 0.95 patients per centre per month in UK publicly funded trials (Walters 2017; Jacques 2022; D01).
Show data
| Factor | United States | United Kingdom | Spain | Poland | Turkey | India |
|---|---|---|---|---|---|---|
| Therapeutic area | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 | 0.300 |
| Country | 0.225 | 0.255 | 0.300 | 0.420 | 0.300 | 0.330 |
| Site type | 0.222 | 0.249 | 0.293 | 0.432 | 0.289 | 0.314 |
| Track record | 0.218 | 0.244 | 0.287 | 0.423 | 0.284 | 0.308 |
| Protocol and population | 0.174 | 0.195 | 0.230 | 0.338 | 0.227 | 0.246 |
| Patient acceptability | 0.122 | 0.136 | 0.161 | 0.237 | 0.159 | 0.173 |
| Competing trials | 0.122 | 0.136 | 0.161 | 0.237 | 0.159 | 0.173 |
What this design does to the sites needed
To finish by March 2027 with 85% confidence, this design needs about 197 sites, the same as the protocol as written.
| Country | Per site per month, protocol as written | With this design | Change | Sites needed, protocol | With this design |
|---|---|---|---|---|---|
| United States | 0.122 | 0.122 | – | 8 | 8 |
| United Kingdom | 0.136 | 0.136 | – | 44 | 44 |
| Spain | 0.161 | 0.161 | – | 71 | 71 |
| Poland | 0.237 | 0.237 | – | 41 | 41 |
| Turkey | 0.159 | 0.159 | – | 18 | 18 |
| India | 0.173 | 0.173 | – | 15 | 15 |
Risks these answers switch on
Open a risk to see its effect, what helped, what did not and the sources. Grade A is the strongest evidence and D the weakest.
Protocol and design
PD-01Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) Grade A
- Effect
- Negative; eligible pool ×0.48 to 0.53 against broadened criteria, with the hazard ratio unchanged or better.
- What helped
- ASCO-Friends modernised criteria and the FDA 2020 to 2026 guidances; data-driven criteria; adoption of 54 to 93% by criterion in NCI CTEP protocols.
- What did not
- Laboratory and washout exclusions carried forward unchanged across phases and years.
- Sources
- Harvey 2021; Liu 2021; Kim 2017 and 20212; Unger 2019
PD-02Number of eligibility criteria and complexity growth Grade B
- Effect
- Negative; more criteria independently associated with poor accrual (p = 0.013); complex trials randomise 59% of screened against about 75%.
- What helped
- Upstream protocol feasibility review and benchmarking against Tufts norms.
- What did not
- not found
- Sources
- Carlisle 2015; Getz 2014; Getz 2023
EB-04Restrictive eligibility criteria and protocol complexity Grade B
- Effect
- Negative; more eligibility criteria associated with accrual failure (p=0.013), 21.5% of cancer patients ineligible for an available trial, procedure counts rising 6.5 to 10.5% a year, and tissue sample required OR 1.26 with a CI including 1.
- What helped
- CTTI framework recommends limiting complexity and realistic eligibility (not quantified).
- What did not
- not found
- Sources
- Carlisle 2015; Unger 2019; Getz 2008; Getz 2018; Bennette 2016
PB-02Eligibility criteria exclude patients (comorbidity, age, performance status, language) Grade A
- Effect
- 21.5% (10.9 to 34.6) of patients with an open trial are ineligible; any comorbidity cuts participation odds to 0.76; 81.3% of high-impact RCTs exclude common conditions; 19% of US trials require English.
- What helped
- Broadening criteria: dropping the comorbidity restrictions ASCO recommends removing could add up to 6,317 registrations a year; translation widens the pool.
- What did not
- not found
- Sources
- Unger 2019 JNCI; Unger 2019 JAMA Oncol; Van Spall 2007; Muthukumar 2021
PD-12Biomarker-selected population with low marker prevalence Grade B
- Effect
- Negative; 37.6% actionable and 17.8% assigned in NCI-MATCH; 39 to 70% amyloid-negative at screening; MASH screen failure 56%.
- What helped
- Central screening at scale (1,117 sites); EHR and registry pre-screening.
- What did not
- not found
- Sources
- Flaherty 2020; Sevigny 2016; Sperling 2020; Souza 2025
PD-05Placebo or no-added-treatment control arm Grade B
- Effect
- Negative; willingness 30% against 39%; acceptance 60.5% against 80.6%.
- What helped
- All-active arms; add-on designs; equipoise-focused recruiter training through the QRI.
- What did not
- not found
- Sources
- Welton 1999; Jenkins 2000; Mills 2006; Uzzan 2023
PD-17Active comparator (against placebo) in registry data Grade B
- Effect
- Negative association only; poor accrual 23% against 16%.
- What helped
- not found
- What did not
- not found
- Sources
- Carlisle 2015
PD-06Blinded placebo-controlled against open design Grade A
- Effect
- Negative for blinding; an open design adds 10 percentage points (95% CI 7 to 13), high certainty.
- What helped
- Open or PROBE design where scientifically acceptable.
- What did not
- User-tested information leaflets added 1 point, no effect.
- Sources
- Treweek 2018
EB-03Blinded placebo-controlled design instead of open-label Grade A
- Effect
- Open design recruits 10 percentage points more of eligible patients (95% CI 7 to 13); at trial level active-comparator trials failed accrual more often than placebo trials (23% against 16%), and per-centre rates did not differ significantly.
- What helped
- Open-label or pragmatic design where scientifically acceptable (high certainty).
- What did not
- not found
- Sources
- Treweek 2018; Carlisle 2015; Walters 2017; Jacques 2022
PD-09Washout periods and concomitant-medication exclusions Grade C
- Effect
- Negative and qualitative; IBD patients deterred; criteria often arbitrary.
- What helped
- Remove arbitrary washouts, as the FDA final guidance of July 2026 requires.
- What did not
- not found
- Sources
- Harvey 2021 washout group; Liu 2021; Uzzan 2023
PD-10Run-in period before randomisation Grade C
- Effect
- Negative for randomised yield; narrows the population and overstates benefit.
- What helped
- Use only where there is a scientific need.
- What did not
- not found
- Sources
- Pablos-Méndez 1998
PD-20Decentralised elements Grade C
- Effect
- Unclear; modelled value only; sites split on whether they add or remove burden.
- What helped
- Hybrid elements for follow-up visits.
- What did not
- A fully remote trial under-recruited despite a very large outreach funnel.
- Sources
- FDA 2024; DiMasi 2023; Nassif 2023; Florez 2024
SH-29Standard-of-care change Grade B
- Effect
- 11% of non-data terminations on ClinicalTrials.gov came from external information or product withdrawal.
- What helped
- Protocol amendment of the comparator.
- What did not
- not found
- Sources
- Williams et al. 2015
Site
S-06Site type: activation speed Grade A
- Effect
- Negative for academic and hospital sites: median 8.1 months versus 4.4 months for independent sites; 9% versus 54% start within 60 days; 21%, 34%, and 80% within 60 days for AMCs, hospital systems, and investigative sites.
- What helped
- Standardised start-up workflow with a site navigator (133 versus 277 days). Master contracts. UK National Contract Value Review (305 to 194 days).
- What did not
- Sequential review layers. Pre-activation amendments, which add 4 to 6 weeks each.
- Sources
- Smith (WCG) 2024; Advarra 2020; WCG 2025; Dilts and Sandler 2006
S-04Past performance as a predictor Grade B
- Effect
- Positive but modest: Spearman 0.13 to 0.16 for historical rate alone and 0.37 to 0.46 with patient-volume data; well-performing sites have a 70% higher chance of out-performing; trial-manager predictions reach 82% sensitivity but 32% specificity.
- What helped
- Combine historical rate with real-world patient volume, referral flow, and research experience. Guided prediction forms with red flags.
- What did not
- Historical performance alone. Unguided judgement after the initiation visit.
- Sources
- Getz 2011; Hulstaert 2024; Bruhn 2019; Yang 2018; Ninh 2026
S-21Competing trials Grade B
- Effect
- Negative when the eligible pool is scarce: OR 1.88 (1.32 to 2.68) for low accrual per competing trial per 10,000 eligible patients per year; no effect when the pool is large; 3,042 immuno-oncology trials sought 577,076 patients.
- What helped
- Redirect referrals to non-overlapping sites and re-engage the PI (anecdotal). Choose indications and regions with slack.
- What did not
- Adding sites into the same saturated pool.
- Sources
- Bennette 2016; Hutchinson 2022; Tang 2018; ClinOops 2026
Sponsor, CRO and model
S-18Technology burden Grade B
- Effect
- Negative on site time, unquantified for enrolment: 60% of sites use 20 or more systems daily, about 10 to 12 applications per site in 2015, 46% say too many separate technologies and 74% cite login tracking (2020), 40% of sites spend 5 to 15 hours per month per study on unpaid training, and 19% rank sponsor technology a top challenge.
- What helped
- Accept site-preferred systems. Consistent technology across a sponsor's studies. Paid training.
- What did not
- not found
- Sources
- WCG 2024; SCRS 2023 Site Landscape; Bechtel 2024; Florence 2024; SCRS 2020